

# Julie Sheldon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6338574/julie-sheldon-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

3,156  
citations

30  
h-index

56  
g-index

61  
ext. papers

3,482  
ext. citations

8.2  
avg, IF

4.83  
L-index

#	Paper	IF	Citations
60	Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
59	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	9
58	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. <i>Gut</i> , <b>2020</b> , 69, 1659-1666	19.2	5
57	Viral fitness: history and relevance for viral pathogenesis and antiviral interventions. <i>Pathogens and Disease</i> , <b>2019</b> , 77,	4.2	19
56	Quasispecies and Drug Resistance <b>2017</b> , 123-147		1
55	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3786-93	5.9	29
54	Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 312-9	13.4	12
53	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 219-26	9.7	64
52	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , <b>2015</b> , 7, 3995-4046	6.2	38
51	Supercritical fluid extraction of heather ( <i>Calluna vulgaris</i> ) and evaluation of anti-hepatitis C virus activity of the extracts. <i>Virus Research</i> , <b>2015</b> , 198, 9-14	6.4	15
50	Molecular basis of interferon resistance in hepatitis C virus. <i>Current Opinion in Virology</i> , <b>2014</b> , 8, 38-44	7.5	20
49	Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. <i>Journal of Virology</i> , <b>2014</b> , 88, 12098-111	6.6	57
48	Quasispecies and Drug Resistance <b>2014</b> , 1-22		
47	Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. <i>Journal of Virology</i> , <b>2013</b> , 87, 7593-607	6.6	64
46	Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. <i>PLoS ONE</i> , <b>2013</b> , 8, e71039	3.7	52
45	Viral quasispecies evolution. <i>Microbiology and Molecular Biology Reviews</i> , <b>2012</b> , 76, 159-216	13.2	677
44	Seroreversion of hepatitis C virus (HCV) antibodies in an HIV-infected patient despite continuous HCV replication. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1634-5	11.6	8

43	The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. <i>Hepatology</i> , <b>2009</b> , 49, 1158-65	11.2	103
42	Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. <i>Aids</i> , <b>2009</b> , 23, 268-72	3.5	20
41	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 626-7	5.1	15
40	Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 766-8	5.1	104
39	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , <b>2008</b> , 5, 86-93	5.9	7
38	Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , <b>2008</b> , 13, 1-19	3.7	39
37	Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 97-102	1.6	22
36	Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients?. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 97-102	1.6	59
35	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , <b>2007</b> , 54, 173-9	18.9	30
34	Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 1171-81	5.9	24
33	Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 1129-35	7.5	54
32	Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 44, 557-61	3.1	46
31	Human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in an HIV-positive patient coinfecting with human T lymphotropic virus type 2 following initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, e118-20	11.6	11
30	Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 88-92	9.7	19
29	Telbivudine: a new option for the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 751-61	5.4	32
28	Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. <i>Aids</i> , <b>2007</b> , 21, 2253-4	3.5	4
27	Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. <i>Aids</i> , <b>2007</b> , 21, 652-3	3.5	2
26	Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 279-82	3.1	49

25	Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1599-608	19.7	26
24	Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 709-13	5.1	69
23	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , <b>2006</b> , 20, 1951-4	3.5	58
22	Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. <i>Aids</i> , <b>2006</b> , 20, 451-3	3.5	9
21	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 2831-42	4	1
20	Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 727-34	1.6	87
19	Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 727-734	1.6	183
18	Mother-to-child transmission of human herpesvirus-8 in South Africa. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1068-75	7	107
17	Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). <i>Virus Research</i> , <b>2002</b> , 82, 115-26	6.4	42
16	No Increased Human Herpesvirus 8 Seroprevalence in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 26, 182-184	3.1	15
15	No increased human herpesvirus 8 seroprevalence in patients with HIV-associated non-Hodgkin's lymphoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 26, 182-4	3.1	7
14	B-lymphotropic viruses in a novel tropical splenic lymphoma. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 161-6	4.5	12
13	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. <i>Journal of Medical Virology</i> , <b>2001</b> , 65, 123-132	19.7	50
12	Recombination in human herpesvirus-8 strains from Uganda and evolution of the K15 gene. <i>Journal of General Virology</i> , <b>2001</b> , 82, 2393-2404	4.9	50
11	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays <b>2001</b> , 65, 123		3
10	Human herpes virus 8 infection in kidney transplant patients in Belgium. <i>Nephrology Dialysis Transplantation</i> , <b>2000</b> , 15, 1443-5	4.3	18
9	Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: Variable frequencies found in a multicenter serological study. <i>Journal of Medical Virology</i> , <b>2000</b> , 62, 498-504	19.7	34
8	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. <i>Blood</i> , <b>2000</b> , 96, 2355-2357	2.2	43

7	Bone marrow failure associated with human herpesvirus 8 infection after transplantation. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1378-85	59.2	190
6	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. <i>Blood</i> , <b>2000</b> , 96, 2355-2357	2.2	12
5	Evidence for horizontal and not vertical transmission of human herpesvirus 8 in children born to human immunodeficiency virus-infected mothers. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 795-9	3.4	43
4	Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d'Ule de France (GCIF). <i>Transplantation</i> , <b>1999</b> , 67, 1236-42	1.8	87
3	Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. <i>International Journal of Cancer</i> , <b>1998</b> , 77, 817-20	7.5	199
2	Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1998</b> , 338, 1585-90	59.2	96
1	Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents <b>1998</b> , 77, 817		2